Connect with us


Studying the Effects of Natural Psilocybin Versus Synthetic Versions

Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic…



Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic benefits for individuals suffering from anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorders (OCD). Spearheaded by Professor Bernard Lerer, this research delves into the realm of psychedelics as a promising avenue for treating psychiatric conditions that have proven resistant to conventional therapies, including PTSD, depression, and potentially even schizophrenia.

Professor Lerer, who serves as both a psychiatry professor and the director at the Hadassah BrainLabs Center for Psychedelic Research at Hebrew University, highlighted the growing body of evidence suggesting that extracts from psilocybin-containing mushrooms may exert effects that are both quantitatively and qualitatively distinct from those observed with chemically synthesized psilocybin. This distinction formed the cornerstone of their investigation, given that current clinical research has largely focused on the latter.

The concept of the “entourage effect” is central to the researchers’ hypothesis. This theory posits that the therapeutic efficacy of psychedelics might not solely be attributable to their primary psychoactive components but could also derive significant benefits from the synergy with other nonpsychoactive compounds present in natural extracts. To explore this theory further, the study involved adult male mice segregated into three distinct groups for comparative analysis: one received chemically synthesized psilocybin, another was administered mushroom extract, and a control group was given a saline solution.

The study aimed to unravel whether the presence of additional compounds in mushroom extracts could enhance therapeutic benefits beyond those offered by synthetic psilocybin alone. Through assessments like the head twitch response and analysis of synaptic protein levels—key markers of neuroplasticity and immediate behavioral effects—the researchers uncovered noteworthy findings.

Notably, administration of mushroom extract resulted in a significant uptick in synaptic proteins such as PSD95, GAP43, SV2A, and synaptophysin in certain brain regions. These proteins play crucial roles in synaptic development, growth, and plasticity, suggesting that mushroom extracts could foster a more robust neuroplastic response compared to their synthetic counterparts.

Furthermore, the study observed metabolic changes in the frontal cortex of mice treated with mushroom extracts, hinting at a unique metabolic state conducive to therapeutic outcomes. Interestingly, both the synthetic psilocybin and mushroom extract triggered a head twitch response in mice, indicating similar acute effects from both treatments.

Published in the “Molecular Psychiatry” journal, these findings signal a potentially significant advancement in the use of psychedelic compounds for mental health treatment. The implications of this research are likely to capture the interest of pioneering companies like Mind Medicine Inc., which are dedicated to developing therapeutic solutions based on hallucinogenic compounds, including magic mushrooms. This burgeoning field of study promises to unlock new pathways for addressing some of the most challenging mental health disorders faced today.

Read More



NXTpsychedelics is part of NXT Financial Media Group. Copyright 2021 media